Longeveron (LGVN) AI Stock Analysis

• Market Cap: $20.48M
• Dividend Yield: N/A
• Average Volume (3M): 473.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -22.41%
• EPS Growth: 78.88%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.23
• Shares Outstanding: 19,848,877
• 10 Day Avg. Volume: 706,553
• 30 Day Avg. Volume: 473,105
• PEG Ratio: -0.02
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 7.42
• P/FCF Ratio: -0.48
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 11.58
• Enterprise Value/Gross Profit: 15.47
• Enterprise Value/Ebitda: -0.81
• 1Y Price Target: $2.00
• Price Target Upside: 270.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.84
• Revenue Forecast (FY): $715.67K

• Rating: 53 Neutral
• Price Target: $0.97 ▲(80.37% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is held back primarily by weak financial performance (persistent losses and cash burn with elevated financing/dilution risk). Offsetting this are constructive technical momentum signals and an earnings-call backdrop with clear clinical catalysts and extended runway from recent financing, though valuation remains difficult to support given negative earnings and no dividend.

Positive Factors

Scientific Validation & IP

High-profile peer-reviewed publications and multiple issued patents create durable scientific credibility and a potential intellectual-property moat. This supports partner interest, licensing leverage, and long-term platform value that can persist beyond single trials and attract non-dilutive collaborations.

Pivotal HLHS Program with Regulatory Upside

A completed pivotal enrollment and scheduled topline readout create a clear, time‑durable regulatory catalyst. Rare pediatric designation and PRV eligibility provide structural commercial/regulatory optionality, which if positive materially improves approval and monetization pathways beyond short‑term market moves.

Management Restructuring and Cost Discipline

Installing a veteran biotech CEO tied to fundraising and implementing aggressive cost controls signals strengthened operational governance. Durable if retained: better capital allocation, focused execution on pivotal milestones, and a track record of conserving runway improve chances to reach critical de-risking events.

Negative Factors

Weak Financial Performance

Revenue is small and volatile while operating and net losses are large and persistent, producing chronically negative operating cash flow. Over multiple years this erodes equity, increases financing dependence, and limits the company's ability to self-fund trials or scale commercial operations without partners.

Near-Term Liquidity Risk

Low year-end cash and a runway tied to milestone-based financing and potential PRV proceeds create structural financing fragility. Reliance on contingent capital sources increases execution risk, can delay programs, and forces strategic choices that may prioritize liquidity over optimal clinical timelines.

Dilution & Complex Financing Terms

The financing structure introduces convertible preferred shares with protective rights and a revenue-sharing clause on any PRV sale. These terms raise dilution risk and reduce downstream economic upside for existing shareholders, potentially complicating future raises and partner negotiations over durable value capture.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

How the Company Makes Money

null

Longeveron Financial Statement Overview

Summary

Financials are weak: small and declining revenue, persistent large operating/net losses, and consistently negative operating cash flow/free cash flow indicating ongoing cash burn and reliance on external financing. Balance-sheet leverage is modest, but equity and assets have declined sharply by 2025, increasing dilution/financing risk.

Income Statement

Revenue is small and volatile, with 2025 revenue down materially versus 2024 (while 2024 showed growth off a low base). Profitability is weak and persistent: the company has reported large operating and net losses every year, with margins deeply negative across the period, indicating a cost structure far above current revenue capacity. A positive is that gross profit is consistently positive (the product/service economics are not the core issue), but the scale of operating expenses keeps losses elevated.

Balance Sheet

Leverage appears low in recent years, with modest total debt relative to equity in 2022–2024, which reduces near-term balance-sheet pressure. However, equity has dropped sharply by 2025 versus prior years, which weakens the capital cushion and highlights ongoing burn and/or dilution risk. Overall assets have also declined meaningfully from earlier periods, signaling a smaller financial base to support continued losses.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are deeply negative each year, reflecting sustained cash burn. While free cash flow improved in 2024 and again in 2025 versus 2024, the absolute outflows remain large, implying continued reliance on external financing. A relative positive is that cash burn broadly tracks accounting losses (free cash flow is roughly in line with net loss in multiple years), suggesting losses are not being masked by large non-cash addbacks.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.44M	1.20M	2.39M	709.00K	1.22M	1.31M
Gross Profit	1.08M	803.00K	1.88M	221.00K	497.00K	590.00K
EBITDA	-20.52M	-23.29M	-15.56M	-20.08M	-17.15M	-16.13M
Net Income	-21.34M	-22.70M	-15.97M	-21.41M	-18.84M	-17.05M
Balance Sheet
Total Assets	15.56M	10.26M	25.56M	12.08M	27.41M	42.77M
Cash, Cash Equivalents and Short-Term Investments	9.24M	4.66M	19.23M	5.36M	19.66M	35.04M
Total Debt	983.00K	824.00K	1.45M	2.04M	2.60M	3.14M
Total Liabilities	5.59M	499.00K	3.67M	5.34M	6.91M	5.31M
Stockholders Equity	9.97M	5.67M	21.89M	6.74M	20.50M	37.45M
Cash Flow
Free Cash Flow	-16.98M	-18.64M	-14.86M	-19.30M	-14.82M	-10.95M
Operating Cash Flow	-16.72M	-18.64M	-13.87M	-19.00M	-13.97M	-9.64M
Investing Cash Flow	-654.00K	-595.00K	-640.00K	8.19M	-677.00K	-10.70M
Financing Cash Flow	3.84M	4.67M	28.79M	5.26M	-509.00K	45.17M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Positive. The current price of 0.54 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.60, and below the 200-day MA of 0.86, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 69.77 is Neutral, neither overbought nor oversold. The STOCH value of 64.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGVN	53 Neutral	$20.48M	-0.39	-119.92%	―	-22.41%	78.88%
EDSA	52 Neutral	$58.44M	-1.26	-55.75%	―	―	30.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	51 Neutral	$84.98M	-5.32	-71.26%	―	185.71%	79.03%
FBLG	44 Neutral	$18.67M	-0.77	-1292.87%	―	―	18.47%
PCSA	41 Neutral	$7.16M	-0.66	-301.42%	―	―	72.88%
CMMB	39 Underperform	$12.68M	-2.33	-89.92%	―	―	53.19%

Longeveron Corporate Events

Longeveron Announces $30 Million Private Placement Financing

On March 10, 2026, Longeveron entered into a securities purchase agreement for a private placement of up to approximately $30 million, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare funds, priced at-the-market under Nasdaq rules. The initial closing on March 11, 2026, raised about $15 million through the sale of 6,013,384 Class A common shares at $0.52 and 11,873.04 Series A non-voting convertible preferred shares, immediately convertible at the same price into 22,832,770 common shares, alongside an investor right to 50% of potential net proceeds from any future sale of an FDA Rare Pediatric Disease Priority Review Voucher tied to the laromestrocel HLHS program.

Concurrently, Longeveron filed a Certificate of Designation in Delaware authorizing up to 26,975 Series A preferred shares, which carry no general voting or liquidation preference but receive dividends on an as-converted basis and grant holders protective voting rights over key corporate actions and further preferred issuance. The financing is expected to extend the company’s cash runway into the fourth quarter of 2026, past the anticipated third-quarter 2026 topline readout of the pivotal Phase 2b ELPIS II trial in HLHS, positioning Longeveron to advance its laromestrocel pipeline while introducing potential dilution and a future revenue-sharing component linked to any priority review voucher sale for stakeholders to consider.

The most recent analyst rating on (LGVN) stock is a Hold with a $0.53 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Appoints New CEO Amid Cost-Cutting Initiatives

On February 9, 2026, interim CEO Than Powell resigned from his temporary role at Longeveron but remained with the company in business development, as the board appointed veteran biotech executive Stephen H. Willard as permanent CEO effective February 11, 2026. Longeveron tied Willard’s compensation to a mix of cash and equity, including substantial stock and option grants, while simultaneously imposing a temporary 50% pay cut on its CEO and executive chairman and rolling out broader cost-cutting measures such as employee furloughs and reduced board fees to conserve cash ahead of pivotal clinical trial milestones.

The leadership change comes as Longeveron sharpens its corporate focus on delivering top-line data from its pivotal Phase 2b trial of laromestrocel in hypoplastic left heart syndrome expected in the third quarter of 2026, which the FDA has indicated could support a future biologics license application if successful. The combination of a seasoned fundraiser at the helm, equity-heavy executive packages and aggressive cost-containment efforts underscores the company’s drive to extend its capital runway and strengthen its position in the competitive regenerative medicine space at a critical juncture for its lead asset.

The most recent analyst rating on (LGVN) stock is a Hold with a $0.53 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.